港股異動 | 名創優品漲超7% 2022財年扭虧為盈 淨賺6.38億元
格隆匯9月30日丨名創優品(9896.HK)跳空高開,現漲7.22%,報9.5港元,總市值120億港元。公司昨日晚公吿,截至2022財年全年營收100.9億元,去年同期為90.7億元,同比增長11.2%;淨利潤6.38億元,上一年同期為虧損14.2億元。報吿期內,門店網絡銷售的產品GMV總計約184.0億元。此外,擬根據股份購回計劃,在公開市場購回最多價值1億美元股份。董事會主席葉國富擬於未來1年斥最多500萬美元增持股份。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.